CSIMarket
 
Oncolytics Biotech Inc   (ONCY)
Other Ticker:  
 
 
Price: $1.0300 $0.00 0.000%
Day's High: $1.05 Week Perf: -4.63 %
Day's Low: $ 1.02 30 Day Perf: 0.98 %
Volume (M): 81 52 Wk High: $ 3.08
Volume (M$): $ 83 52 Wk Avg: $1.45
Open: $1.03 52 Wk Low: $0.88



 Market Capitalization (Millions $) 70
 Shares Outstanding (Millions) 68
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Oncolytics Biotech Inc
Oncolytics Biotech Inc is a biopharmaceutical company that focuses on the development of oncolytic viruses for the treatment of cancer. Their primary product candidate is called Reolysin, which is a proprietary formulation of the human reovirus.

The company's approach involves using the reovirus to selectively target and kill cancer cells, while leaving healthy cells unharmed. This unique concept is based on the fact that certain cancer cells have an abnormal signaling pathway, which allows the reovirus to replicate within those cells and induce cell death.

Oncolytics Biotech conducts clinical trials to test the efficacy and safety of Reolysin in various types of cancer, including breast, lung, and pancreatic cancer. The company also collaborates with other pharmaceutical companies to investigate combination therapies and expand the potential of their oncolytic virus technology.

In addition to Reolysin, Oncolytics Biotech also has a pipeline of other oncolytic virus candidates under development for the treatment of different types of cancer. Their goal is to offer new and innovative treatment options for patients with limited therapeutic alternatives.

Overall, Oncolytics Biotech Inc is a biopharmaceutical company dedicated to developing oncolytic viruses as a novel approach to fighting cancer, with the aim of improving patient outcomes and quality of life.


   Company Address: 804, 322 11th Avenue SW Calgary 0 AB
   Company Phone Number: 670-7377   Stock Exchange / Ticker: NASDAQ ONCY
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Oncolytics Biotech Inc

ONCY Faces Setback in Fourth Quarter, But Shows Promise for Future Growth in Major Pharmaceutical Preparations Industry

As the October to December 31, 2023 reporting cycle comes to a close, the Major Pharmaceutical Preparations industry has seen some interesting developments. One company in particular, ONCY, reported an operating loss of $-25.883906 million for the fourth quarter of 2023. While this may seem like a significant setback, it is important to remember that setbacks are often a stepping stone to success in the business world.
In the quest to establish a successful business model, companies sometimes face challenges that result in financial losses. ONCY's recent fiscal fourth quarter results may not have been ideal, with a deficit of $-21.258 million and a revenue of $0.00 million. However, it is important to note that the company has managed to decrease its loss per share to $-0.31 from $-0.33 in the previous fiscal year.

Clinical Study

Anal Cancer Treatment Market Projected to Reach $1.63 Billion by 2030 with Growing Focus on New Therapies

Published Wed, Feb 14 2024 1:31 PM UTC

The global anal cancer treatment market is expected to see significant growth in the coming years, with projections indicating it will reach USD 1.63 billion by 2030. A recent article featured on the MD Anderson website highlights the rising prevalence of anal cancer, particularly among women, and the importance of early detection for successful treatment. The report also ou...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com